PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsLatanoprost
Xalatan, Roclanda(latanoprost)
Iyuzeh, Latanoprost, Rocklatan, Roclanda, Xalatan (latanoprost) is a small molecule pharmaceutical. Latanoprost was first approved as Xalatan on 1996-06-05. It is used to treat open-angle glaucoma in the USA. It has been approved in Europe to treat ocular hypertension and open-angle glaucoma. The pharmaceutical is active against prostaglandin F2-alpha receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
eye diseasesD005128
Trade Name
FDA
EMA
Iyuzeh, Latanoprost, Xalatan (discontinued: Latanoprost, Xelpros)
Combinations
Rocklatan
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Latanoprost
Tradename
Company
Number
Date
Products
IYUZEHThea PharmaN-216472 RX2022-12-13
1 products, RLD, RS
XALATANUpjohnN-020597 RX1996-06-05
1 products, RLD, RS
Show 1 discontinued
Latanoprost
+
Netarsudil dimesylate
Tradename
Company
Number
Date
Products
ROCKLATANAlcon ResearchN-208259 RX2019-03-12
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
iyuzehNew Drug Application2024-07-30
latanaprostANDA2011-03-22
latanoprostANDA2025-12-18
latanoprost pfunapproved drug other2018-05-08
latanoprostene bunod ophthalmic solution, 0.024%ANDA2025-05-02
rocklatanNew Drug Application2025-03-19
tim-brim-dor-latunapproved drug other2018-05-08
tim-dor-latunapproved drug other2018-05-08
tim-lat -pfunapproved drug other2018-05-08
vyzultaNew Drug Application2024-02-27
Show 2 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
open-angle glaucomaEFO_0004190D005902H40.1
ocular hypertensionEFO_1001069D009798H40.0
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Latanoprost / Netarsudil Dimesylate, Rocklatan, Alcon Labs Inc
94150432034-03-14DP
99313362034-03-14DS, DPU-1524
99934702034-03-14DS, DPU-1524
105889012034-03-14DS, DPU-1524
111855382034-03-14DP
111978532034-03-14DP
83948262030-11-10DS, DPU-1524
101740172030-01-27DS, DPU-1524
106548442030-01-27DS, DPU-1524
110280812030-01-27U-1524
116187482030-01-27U-1524
84503442026-07-11DS, DPU-1524
90965692026-07-11DS, DPU-1524
105329932026-07-11U-1524
108828402026-07-11U-1524
110214562026-07-11U-1524
Latanoprost, Iyuzeh, Thea Pharma
86370542031-07-08DPU-446
Latanoprost, Xelpros, Sun Pharm
96298522029-09-12DP
95392622028-10-15U-2400
ATC Codes
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01E: Antiglaucoma preparations and miotics
— S01EE: Prostaglandin analogues, antiglaucoma drugs and miotics
— S01EE01: Latanoprost
— S01EE51: Latanoprost and netarsudil
HCPCS
No data
Clinical
Clinical Trials
277 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GlaucomaD005901EFO_0000516H401457417039215
Ocular hypertensionD009798EFO_1001069H40.01553474821177
Open-angle glaucomaD005902EFO_0004190H40.11249434016155
HypertensionD006973EFO_0000537I101143292314113
Eye diseasesD005128EFO_0003966H44—1—5—6
Intraocular pressureD007429———1—135
Alopecia areataD000506EFO_0004192L6321—114
AlopeciaD000505—L6421—114
VitiligoD014820EFO_0004208L80—321—4
Angle-closure glaucomaD015812————1113
Show 13 more
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CataractD002386EFO_0001059H26.9—1———1
Meniere diseaseD008575EFO_0006862H81.0—1———1
HypopigmentationD017496———1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypotrichosisD007039——1————1
Treatment outcomeD016896——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MyopiaD009216EFO_0003927H52.1————22
Ocular physiological phenomenaD009799——————22
Corneal diseasesD003316—H18.9————22
Exfoliation syndromeD017889EFO_0004235—————22
Ganglion cystsD045888—M67.4————11
SyndromeD013577——————11
Regional blood flowD012039——————11
PseudophakiaD019591——————11
Corneal edemaD015715EFO_1000879H18.20————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLatanoprost
INNlatanoprost
Description
Latanoprost is a prostaglandin Falpha that is the isopropyl ester prodrug of latanoprost free acid. Used in the treatment of open-angle glaucoma and ocular hypertension. It has a role as an antiglaucoma drug, an antihypertensive agent, an EC 4.2.1.1 (carbonic anhydrase) inhibitor and a prodrug. It is a prostaglandins Falpha, a triol and an isopropyl ester. It is functionally related to a latanoprost free acid.
Classification
Small molecule
Drug classprostaglandins
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1
Identifiers
PDB—
CAS-ID130209-82-4
RxCUI—
ChEMBL IDCHEMBL1051
ChEBI ID6384
PubChem CID5311221
DrugBankDB00654
UNII ID6Z5B6HVF6O (ChemIDplus, GSRS)
Target
Agency Approved
PTGFR
PTGFR
Organism
Homo sapiens
Gene name
PTGFR
Gene synonyms
NCBI Gene ID
5737
Protein name
prostaglandin F2-alpha receptor
Protein synonyms
FP prostanoid receptor, PGF receptor, PGF2 alpha receptor, prostaglandin receptor (2-alpha), Prostanoid FP receptor
Uniprot ID
Q9P1X4
Mouse ortholog
Ptgfr (19220)
prostaglandin F2-alpha receptor (P43117)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Xalatan – Pfizer
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Xalatan – Viatris
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Latanoprost
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 5,092 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
26,049 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use